Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.45 USD
-0.15 (-4.17%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $3.41 -0.04 (-1.16%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 8/1/24 |
---|---|
Current Quarter | -0.46 |
EPS Last Quarter | -0.42 |
Last EPS Surprise | 10.64% |
ABR | 2.74 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -1.84 |
Next Year | -1.86 |
EPS (TTM) | -1.88 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | NA |
# of Estimates | NA | NA | NA | NA |
High Estimate | NA | NA | NA | NA |
Low Estimate | NA | NA | NA | NA |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.46 | -0.46 | -1.84 | -1.86 |
# of Estimates | 2 | 2 | 3 | 1 |
Most Recent Consensus | -0.45 | -0.46 | -1.83 | NA |
High Estimate | -0.45 | -0.46 | -1.83 | -1.86 |
Low Estimate | -0.46 | -0.46 | -1.85 | -1.86 |
Year ago EPS | -0.54 | -0.45 | -2.02 | -1.84 |
Year over Year Growth Est. | 14.81% | -2.22% | 8.91% | -1.09% |
Agreement - Estimate Revisions
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 1 | 1 | 1 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 0 |
Down Last 60 Days | 0 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.46 | -0.46 | -1.84 | -1.86 |
7 Days Ago | -0.46 | -0.46 | -1.84 | -1.86 |
30 Days Ago | -0.46 | -0.46 | -1.84 | -1.86 |
60 Days Ago | -0.47 | -0.48 | -1.88 | -1.74 |
90 Days Ago | -0.47 | -0.48 | -1.88 | -1.74 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (6/2024) |
Next Qtr (9/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.46 | -0.46 | -1.84 | -1.86 |
Zacks Consensus Estimate | -0.46 | -0.46 | -1.84 | -1.86 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (3/2024) |
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.42 | -0.47 | -0.45 | -0.54 | NA |
Estimate | -0.47 | -0.50 | -0.58 | -0.65 | NA |
Difference | 0.05 | 0.03 | 0.13 | 0.11 | 0.08 |
Surprise | 10.64% | 6.00% | 22.41% | 16.92% | 13.99% |
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more